Clinical Trials Results - National Cancer Institute

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

In English \| En español
Search

NCI Home

Cancer Topics


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 932 for your search:

Drug:  carboplatin
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without SCH 58500 in Patients with Newly Diagnosed Stage III Ovarian Epithelial or Primary Peritoneal Cancer With No Greater Than 2 cm Residual Disease Following Surgery (Summary Last Modified 07/2001)

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SPRI-C/I98-102, SPRI-C98-102, NCI-V99-1544, NCT00003880

Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without BMS-275291 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-BR18, BMS-CA161-003, NCT00006229, BR18

Phase II/III Randomized Study of Gemcitabine and Carboplatin Versus Methotrexate, Carboplatin, and Vinblastine in Previously Untreated Patients With Transitional Cell Cancer of the Urothelium Who are Ineligible for Cisplatin-Based Chemotherapy

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-GU-30986, NCT00014274

Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-4599, CALGB-E4599, E4599, NCT00021060

Phase II/III Chemotherapy with MVP (MITO/VBL/CACP) vs CHIP vs CBDCA vs VBL/CACP vs MVP-CAMP (MITO/VBL/CACP/CTX/ADR/MTX/PCB) in Patients with Metastatic (Stage III) non-Small Cell Bronchogenic Carcinoma

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: EST-1583

Phase II/III Comparison of the Platinum Compounds CBDCA vs CHIP vs CACP for Recurrent or Metastatic Epidermoid Carcinoma of the Head and Neck

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: UMCC-8223

Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 16 to physiologic 70
Sponsor: NCI
Protocol IDs: CLB-8642, CALGB-8642

Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: POG-8741/42, POG-8741, POG-8742

Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 0 to 18
Sponsor: NCI
Protocol IDs: CCG-3891

10.

Phase II/III Randomized Study of Paclitaxel and Carboplatin With Versus Without Cediranib Maleate in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, NCT00245154, BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B

11.

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 40 to 75
Sponsor: Other
Protocol IDs: Hamamatsu 18-66, NCT00752115

12.

Phase III Randomized Study of G-CSF Priming Prior to Neoadjuvant TAX/CBDCA Followed by a Phase I Dose-Seeking Study of TAX/CBDCA During Definitive Radical Thoracic Irradiation for Stages IIIB/Bulky IIIA Nonsmall Cell Lung Cancer (Summary Last Modified 12/95)

Phase: Phase III, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: FCCC-94001, NCI-V94-0479

13.

Phase III Randomized Comparison of Combination Chemotherapy with CBDCA/CTX vs CACP/CTX in Patients with Stage III/IV Ovarian Carcinoma

Phase: Phase III, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-8412

14.

Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma (Summary Last Modified 03/97)

Phase: Phase III
Type: Treatment
Status: Completed
Age: no greater than 60
Sponsor: NCI
Protocol IDs: NU-93B1, NCI-T93-0058D, T93-0058

15.

Phase III Randomized Study of Salvage Using Cisplatin, Etoposide, and Ifosfamide (PEI) or Vinblastine, Ifosfamide, and Cisplatin (VeIP) With or Without High-Dose Carboplatin, Etoposide, and Cyclophosphamide, Followed by Autologous Bone Marrow and/or Peripheral Blood Stem Cell Transplantation in Male Patients With Germ Cell Tumors in Relapse or First Partial Remission (Summary Last Modified 07/2001)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: FRE-IT94, FRE-FNCLCC-IT94, NCI-F94-0019, NCT00002566

16.

Phase III Randomized Study of TAX/CDDP vs CTX/CDDP in Patients with Advanced Epithelial Ovarian Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: EORTC-55931, CAN-NCIC-OV10, SCOTTISH-GYN-G42, SGCSG-NOCOVA-9410, OV10

17.

Phase III Randomized Study of Bleomycin, Etoposide, and Cisplatin (BEP) With or Without High-Dose Carboplatin, Etoposide, and Cyclophosphamide Plus Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation in Male Patients With Previously Untreated Poor- or Intermediate-Risk Germ Cell Tumors

Phase: Phase III
Type: Treatment
Status: Completed
Age: 12 and over
Sponsor: NCI
Protocol IDs: MSKCC-94076, CLB-99812, E-3894, SWOG-9442, NCI-T94-0086D, NCT00002596, T94-0086

18.

Phase III Randomized Study of PIXY321 Both Before and After vs Only After ICE (IFF/CBDCA/VP-16) to Ameliorate Myelotoxicity in Patients with Previously Untreated Malignancies (Summary Last Modified 03/96)

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: YALE-HIC-7653, NCI-V94-0553

19.

Phase III Study of Multimodality Therapy Based on Prior Therapy and Histology in Patients With Relapsed Wilms' Tumor

Phase: Phase III
Type: Treatment
Status: Completed
Age: 21 and under at diagnosis
Sponsor: NCI
Protocol IDs: COG-Q9402, NWTS-Q9402, CCG-4942, POG-9444, INT-0152, NWTS-5/R, NCT00002610, Q9402

20.

Phase III Randomized Study of Platinum Compound and Paclitaxel in Optimal Stage III Ovarian Epithelial Cancer: Cisplatin and Paclitaxel (24-Hour Continuous Infusion) vs Carboplatin and Paclitaxel (3-Hour Infusion)

Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: GOG-0158, GOG-0158

21.

Phase III Randomized Study of Surgery With or Without Radiotherapy Versus Radiotherapy Alone After Achieving a Response to a Neoadjuvant Chemotherapy Regimen Containing Cisplatin or Carboplatin in Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: EORTC-08941, NCT00002623

22.

Phase III Randomized Study of High-Dose CBDCA/CTX with G-CSF Followed by Standard-Dose TAX vs High-Dose TAX with G-CSF for Nonpalpable Suboptimal Stage III Ovarian Epithelial Carcinoma (Summary Last Modified 08/98)

Phase: Phase III
Type: Treatment
Status: Closed
Age: adult
Sponsor: NCI
Protocol IDs: SWOG-9249

23.

Phase III Randomized Study of CBDCA/TAX Administered for 3 vs 6 Courses for Selected Stages IA-C and Stages IIA-C Ovarian Epithelial Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: GOG-0157, GOG-0157, GOG-0157

24.

Phase III Randomized Study of CBDCA/5-FU with Pelvic Radiotherapy vs Radiotherapy Alone for Locally Advanced Cervical Cancer (Summary Last Modified 03/2000)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 75 and under
Sponsor:
Protocol IDs: DUT-KWF-CKVO-9407, EU-95013

25.

Phase III Randomized Study of TAX/CBDCA vs CBDCA or CAP (CTX/DOX/CDDP) for Advanced Ovarian Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: MRC-ICON3, EU-95035

Select All on Page

Help with Results

A Service of the National Cancer Institute